On Monday 17 July, the European Commission sent a statement of objections to the pharmaceutical company Teva, amid concerns that a non-commercialisation agreement for a drug it had entered into with Cephalon may be incompatible with EU law.
Several years ago, Cephalon developed Modafinil, a drug to treat sleep disorders. Following the expiry of a number of patents, Teva developed and marketed a cheaper generic drug in the United Kingdom. Following a dispute between the two companies, an...